GSA Capital Partners LLP Makes New $843,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC)

GSA Capital Partners LLP bought a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 45,659 shares of the biopharmaceutical company’s stock, valued at approximately $843,000. GSA Capital Partners LLP owned approximately 0.06% of Revance Therapeutics […]

Related Keywords

Piper Sandler ,Tobin Schilke ,Wells Fargo Company ,Advisor Group Holdings Inc ,Asset Management Americas Inc ,Gsa Capital Partners ,Guggenheim Capital ,Revance Therapeutics Inc ,Proshare Advisors ,Nasdaq ,Barclays ,Securities Exchange Commission ,Capital Partners ,Revance Therapeutics ,Get Rating ,Share Advisors ,Management Americas ,Advisor Group Holdings ,Group Holdings ,Exchange Commission ,Revance Therapeutics Daily ,Nasdaq Rvnc ,Rvnc ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,